Inspire Medical Systems, Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Inspire develops and sells its FDA-approved neurostimulation system for moderate to severe obstructive sleep apnea (OSA), primarily to U.S. hospitals and ambulatory surgery centers. The filing was signed November 7, 2023.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $153.3 million | $109.2 million | $432.3 million | $270.0 million |
| Gross margin | 84.1% | 81.9% | 84.1% | 83.7% |
| Operating loss | $13.5 million | $17.2 million | $49.6 million | $47.3 million |
| Net loss | $8.5 million | $16.8 million | $35.9 million | $48.0 million |
| Basic and diluted loss per share | $0.29 | $0.60 | $1.23 | $1.73 |
Q3 revenue grew 40.4% year over year; nine-month revenue grew 60.1%. U.S. revenue represented 96.2% of Q3 sales and 96.4% for the first nine months. Management attributed growth mainly to greater utilization, penetration in existing territories, new territories, and increased physician and patient awareness. The company reported 274 U.S. sales territories and 1,107 U.S. implanting medical centers at quarter-end.
Gross margin improved year over year, partly because Q3 2022 included $2.8 million of inventory-obsolescence charges. Nine-month gross margin also reflected higher component costs, manufacturing transition expenses, lower sensor yields before process improvements, and supplier-related costs.
Expenses, cash flow, and liquidity
- Operating expenses: Q3 R&D was $29.1 million, up 38.8%; SG&A was $113.2 million, up 32.3%. For nine months, R&D rose 80.4% to $85.5 million and SG&A rose 45.2% to $327.9 million. Growth reflected hiring, stock-based compensation, product development, and increased marketing.
- Cash flow: Nine-month operating cash flow was positive $7.4 million, versus negative $7.7 million in 2022. This included $59.6 million in stock-based compensation and working-capital movements. Investing activities used $143.1 million, primarily for investment purchases and $15.6 million of property and equipment. Financing activities provided $24.1 million, mainly from option exercises and the employee stock purchase plan.
- Liquidity: Cash, cash equivalents, and available-for-sale investments totaled $467.2 million at September 30, 2023, compared with $451.4 million at December 31, 2022. Working capital was $499.6 million. Cash and cash equivalents alone were $329.9 million; short- and long-term investments were $137.3 million.
- Debt and other obligations: No balance remained under the former credit facility, repaid in 2022. Operating lease liabilities were $25.2 million; the company added or amended office and warehouse leases in 2023, extending terms through May 2035.
Outlook, management commentary, and risks
- Management expected 2023 gross margin of 83%–85%. The filing does not provide a specific revenue or earnings forecast.
- The company said existing cash, cash equivalents, investments, and operating cash flow should fund operations and planned capital expenditures for at least 12 months. It anticipated further R&D, SG&A, and capital-spending increases during the remainder of 2023 and 2024, and noted it may need additional financing over time.
- Management cited prior-authorization support changes and continuing ENT surgeon-capacity constraints as factors that adversely affected Q3 revenue growth.
- EU certification for silicone-based leads was expected in Q1 2024 after delays. Until certification or country-specific derogations are obtained, sales in the EU depend on limited supplies of polyurethane-based leads. Management warned of possible procedure delays and up to $4 million of lower European revenue in Q4 2023, potentially extending into early 2024. A Dutch derogation was in place through April 1, 2024 or certification, whichever comes first; approvals in other countries were uncertain.
- Other risks include reliance on single-source suppliers, supply-chain and inflationary pressures, inventory obsolescence, reimbursement and regulatory uncertainty, competition, and the company’s history of losses. The accumulated deficit was $360.2 million. Management also noted uninsured cash balances and potential sensitivity to interest rates.
- In June 2023, the FDA approved an expanded indication raising the upper AHI limit to 100 and the BMI labeling warning to 40; it also approved the SleepSync programmer. A PMA supplement for the next-generation system was submitted in June 2023. Management expected a U.S. SleepSync launch in early 2024. The filing described possible benefit from broader use of GLP-1 weight-loss drugs but said the impact could not be quantified.
- Final 2024 Medicare rates announced in November 2023 included a 1% increase in hospital implantation reimbursement, a 1% decrease for ASCs, and a 6% decrease in physician implantation payment. DISE reimbursement increased substantially. These rates post-date the reporting quarter.
Most important facts for investors to verify
- Whether revenue growth and implant-center expansion continue amid surgeon-capacity constraints and seasonal variability.
- EU MDR certification timing, additional national derogations, lead availability, and realized European revenue impact.
- Whether gross margin remains within management’s 83%–85% 2023 expectation as supply, manufacturing, and product-transition costs evolve.
- How rising R&D, SG&A, advertising, capital expenditures, and stock-based compensation affect losses and cash generation.
- Whether reimbursement changes and broader commercial coverage support procedure growth and customer economics.
- Liquidity needs beyond the stated 12-month horizon, including cash deployment, investment risk, and potential financing requirements.